The Effects of Infliximab Therapy on Health-Related Quality of Life in Ulcerative Colitis Patients
Brian G. Feagan(Western University), Stephen B. Hanauer(Northwestern University), Songkai Yan(Research Triangle Park Foundation), William J. Sandborn(University of San Diego), Paul Rutgeerts(KU Leuven), Mohan Bala, Allan Olson, D. Eisenberg, Jewel Johanns(Johnson & Johnson (United States)), Walter Reinisch(Medical University of Vienna)
Cited by 178
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Crohn's disease
|The Lancet|2012|2.1k